Application of a Biomimetic Nanoparticle-Based Mock Virus to Determine SARS-CoV‑2 Neutralizing Antibody Levels in Blood Samples Using a Lateral Flow Assay

• Published in: Analytical chemistry (Washington) 2024-02, Vol.96 (7), p.2900-2907
• Main Authors: Schobesberger, Silvia, Thumfart, Helena, Selinger, Florian, Spitz, Sarah, Gonzalez, Carla, Pei, Lei, Poglitsch, Marko, Ertl, Peter
• Format: Article
• Language: English
• Subjects: ACE2; Angiotensin; Angiotensin-converting enzyme 2; Antibodies; Assaying; Biomimetics; Blood; Blood levels; COVID-19; Gold; International standards; Nanoparticles; Neutralizing; Peptidyl-dipeptidase A; Sensitivity enhancement; Severe acute respiratory syndrome coronavirus 2; Vaccination; Viral diseases; Viruses
• ISSN: 0003-2700; 1520-6882
• DOI: 10.1021/acs.analchem.3c04372

The presence of neutralizing antibodies against SARS-CoV-2 in blood, acquired through previous infection or vaccination, is known to prevent the (re)­occurrence of outbreaks unless the virus mutates. Therefore, the measurement of neutralizing antibodies constitutes an indispensable tool in assessing an individual’s and a population’s immunity against SARS-CoV-2. For this reason, we have developed an innovative lateral flow assay (LFA) capable of detecting blood-derived neutralizing antibodies using a biomimetic SARS-CoV-2 mock virus system. Here, functionalized gold nanoparticles (AuNPs) featuring the trimeric spike (S) protein at its surface imitate the virus’s structure and are applied to monitor the presence and efficacy of neutralizing antibodies in blood samples. The detection principle relies on the interaction between mock virus and the immobilized angiotensin-converting enzyme 2 (ACE2) receptor, which is inhibited when neutralizing antibodies are present. To further enhance the sensitivity of our competitive assay and identify low titers of neutralizing antibodies, an additional mixing pad is embedded into the device to increase the interaction time between mock virus and neutralizing antibodies. The developed LFA is benchmarked against the WHO International Standard (21/338) and demonstrated reliable quantification of neutralizing antibodies that inhibit ACE2 binding events down to a detection limit of an antibody titer of 59 IU/mL. Additional validation using whole blood and plasma samples showed reproducible results and good comparability to a laboratory-based reference test, thus highlighting its applicability for point-of-care testing.